间充质干细胞治疗顽固性纯红细胞再生障碍疗效观察  

Efficacy of mesenchymal stem cells in the treatment of refractory pure red cell aplasia after major ABO-incompatible hematopoietic stem cell transplantation

作　　者：赵慧芳[1] 李宁[1] 宋永平[1] 魏旭东[1] 房佰俊[1] 

机构地区：[1]河南省肿瘤医院河南省血液病研究所,河南郑州450008

出　　处：《中国现代医学杂志》2010年第20期3167-3169,3172,共4页China Journal of Modern Medicine

基　　金：河南省杰出青年基金(No:0612000900)

摘　　要：目的研究脂肪源间充质干细胞(adipose tissue-derived mesenchymal stem cells,AMSC)作为挽救方案治疗ABO血型不合异基因造血干细胞移植后并发的顽固性纯红细胞再生障碍(pureredcellaplasia,PRCA)的疗效。方法 2例顽固性PRCA患者均经中心静脉输入AMSC(剂量为1.5×106/kg)。结果 2例接受AMSC治疗的患者病情很快得以缓解,均无明显副作用。结论 AMSC有望用于治疗ABO血型不合异基因造血干细胞移植后并发的顽固性PRCA。Objective To study the efficacy of human adipose tissue-derived mesenchymal stem cells （AMSC） as the salvage therapy for refractory pure red cell aplasia （PRCA） after major ABO-incompatible allogeneic hematopoietic stem cell transplantation （allo-HSCT）.MethodsTwo patients with refractory PRCA received intra-venous infusions of AMSC at a dose of 1.5×10^6 per kg of the patients＇weight.ResultsA rapid recovery from PRCA without any side effects was observed. ConclusionsThese results suggest AMSC seems to be a promising therapeutic option in patients with PRCA after ABO-mismatched allo-HSCT, in whom conventional treatment fails.

关 键 词：造血干细胞移植 纯红细胞再生障碍 间充质干细胞 疗效 

分 类 号：R733.7[医药卫生—肿瘤]